Policy ForumMedicine

Stroke--tPA and the Clinic

See allHide authors and affiliations

Science  19 Sep 2003:
Vol. 301, Issue 5640, pp. 1677
DOI: 10.1126/science.1090270

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Clinical trial results are not always rapidly incorporated into routine medical practice. This Policy Forum describes a variety of barriers that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator) for selected patients with acute ischemic stroke. These barriers are not insurmountable but will require a concerted effort to overcome.